Status:
COMPLETED
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
Lead Sponsor:
Sequenom, Inc.
Collaborating Sponsors:
Vitreous -Retina- Macula Consultants of New York
Conditions:
Age Related Macular Degeneration
Choroidal Neovascularization
Eligibility:
All Genders
30+ years
Brief Summary
The study will be designed as a case control evaluation to compare the genetic profiles of three groups of patients categorized according to diagnosis. Group 1 - CNV secondary to CSC Group 2 - CSC wi...
Detailed Description
To determine if patients presenting with type 1 neovascularization believed to be secondary to CSC are genetically distinct from typical CSC patients without neovascularization or patients presenting ...
Eligibility Criteria
Inclusion
- Caucasian
- 30 years and older (CSC)
- 50 years and older (Advanced AMD)
- Genders Eligible for Study: Both
- Completed Consent form
- Diagnosis of choroidal neovascularization in at least one eye
Exclusion
- Patient age less than 30 years (CSC).
- Patient age less than 50 years (AMD).
- Presence of retinal disease involving the photoreceptors and/or outer retinal layers other than AMD and CSC such as high myopia, retinal dystrophies, retinal vein occlusion, diabetic retinopathy and uveitis or similar outer retinal diseases which have been present prior to the age of 30.
- Opacities of the ocular media, limitations of pupillary dilation or other problems sufficient to preclude adequate fundus photography.
- Missing informed consent
- Previous sample donation under this protocol
Key Trial Info
Start Date :
November 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2015
Estimated Enrollment :
152 Patients enrolled
Trial Details
Trial ID
NCT01880788
Start Date
November 1 2012
End Date
August 1 2015
Last Update
September 18 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vitreous Retina Macula Consultants of New York
New York, New York, United States, 10022